Sales were rolled out nationally in 2006.
Realizing the fact that research is a critical growth driver, created a base of strong product and process development skills. Stake in Solemn Biotech. We used this money to build a Greenfield site for API manufacture, as well as for acquisitions. For the acquisitions, typically companies or assets that could be turned around and brought on track were identified.
We make specialty pharmaceuticals and active pharmaceutical ingredients. Our brands are prescribed in chronic therapy areas like, psychiatry, neurology, gastroenterology, and respiratory and dermatology.
We have the same drive for growth that marked our early days. Solemn Biotech came into existence as a startup with just 24 products in 2006. In the time since, We have reached leadership in each of the therapy areas that we operate in, and are rated among the leading companies by key customers. Strengthening market share and keeping this customer focus remains a high priority area for the company.
We have used a combination of internal growth and acquisitions to drive growth; Under a recent corporate development.+ Read More
Nature of Business
NALegal Status of Firm
ProprietorshipAnnual Turnover
40 L - 1.5 CrGST Registration Date
Jul'17Total Number of Employees
11 to 25 PeopleGST Number
23**********1Z9HSN CodeHSN Description
30067000Pharmaceutical goods specified in note 4 to this chapter gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments
30068000Pharmaceutical goods specified in note 4 to this chapter waste pharmaceuticals
- Developed and Managed by IndiaMART InterMESH Limited










